Ingevity Corporation
NGVT
$71.98
$1.061.50%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.18B | 1.17B | 1.18B | 1.18B | 1.11B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.18B | 1.17B | 1.18B | 1.18B | 1.11B |
| Cost of Revenue | 711.70M | 706.10M | 695.90M | 698.90M | 624.60M |
| Gross Profit | 466.00M | 461.50M | 479.90M | 477.60M | 483.30M |
| SG&A Expenses | 170.00M | 171.20M | 167.80M | 161.60M | 152.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 909.80M | 905.70M | 891.20M | 887.20M | 801.20M |
| Operating Income | 267.90M | 261.90M | 284.60M | 289.30M | 306.70M |
| Income Before Tax | -149.40M | -142.00M | -12.60M | -20.80M | -31.00M |
| Income Tax Expenses | 6.60M | 8.30M | 39.30M | 24.40M | 5.30M |
| Earnings from Continuing Operations | -156.00 | -150.30 | -51.90 | -45.20 | -36.30 |
| Earnings from Discontinued Operations | 28.20M | -16.80M | -14.00M | -171.40M | -166.30M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.80M | -167.10M | -65.90M | -216.60M | -353.80M |
| EBIT | 267.90M | 261.90M | 284.60M | 289.30M | 306.70M |
| EBITDA | 363.50M | 361.00M | 381.10M | 386.40M | 410.30M |
| EPS Basic | -3.50 | -4.63 | -1.80 | -5.95 | -9.74 |
| Normalized Basic EPS | 3.14 | 2.93 | 6.07 | 6.08 | 6.79 |
| EPS Diluted | -3.55 | -4.66 | -1.83 | -5.94 | -9.74 |
| Normalized Diluted EPS | 3.11 | 2.91 | 6.05 | 6.08 | 6.78 |
| Average Basic Shares Outstanding | 143.69M | 144.81M | 145.44M | 145.47M | 145.35M |
| Average Diluted Shares Outstanding | 145.10M | 145.74M | 146.36M | 145.90M | 145.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |